GlassScriptPhysician profile
Lindsey Ladd
NPI 1497375786
$1,124.08
in general payments reported to CMS, 2019-2025
18 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $334 · 2023: $259 · 2024: $38.43 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $212.28 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $182.77 | 2022-2025 | Ultomiris |
| Amgen INC. | $97.18 | 2025 | Uplizna |
| Lilly USA, LLC | $96.74 | 2025 | Kisunla |
| Emd Serono, INC. | $71.95 | 2022 | |
| Abbvie INC. | $61.34 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $59.31 | 2023 | Nuplazid |
| Ucb, INC. | $55.58 | 2025 | Fintepla, Rystiggo |
| Lundbeck LLC | $47.41 | 2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $43.14 | 2025 | Hyqvia |
| Pfizer INC. | $34.30 | 2025 | |
| Immedica Pharma US, INC. | $31.27 | 2023 | |
| Genzyme Corporation | $30.08 | 2022 | |
| Ge Healthcare | $23.51 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.37 | 2025 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $20.30 | 2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $20.13 | 2025 | Tremfya |
| Medtronic, INC. | $15.42 | 2025 | Linq II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.